ARTICLE | Clinical News

DA-8159: Phase I data

May 17, 2004 7:00 AM UTC

In a double-blind, placebo-controlled U.K. Phase I trial in 50 healthy volunteers, DA-8159 was well tolerated after a single oral dose up to 400 mg and 10-day repeated doses up to 200 mg. The most fre...